Perspective Therapeutics, Inc. appointed Andrew Bright as Executive Vice-President of Brachytherapy. The appointment advances Perspective Therapeutics' aspirations as a global leader in the manufacturing and distribution of Cesium-131 brachytherapy radioisotope seeds. Brachytherapy seeds have been designed to treat a variety of cancers including prostate, head & neck, lung and brain.

Mr. Bright brings to this role over 30 years in leadership roles within the medical device industry, including over 20 years in brachytherapy. Mr. Bright was part of the commercial enterprise responsible for initial widespread adoption and growth of brachytherapy in the 1990's and was involved in the development and introduction of some of the most successful and clinically relevant products in the industry. Additionally he has extensive US, European, South American and Pacific Rim experience.

He also has prior commercial experience, launching therapeutic radiopharmaceuticals in both Europe and North America.